Developing Clinically Relevant Metastatic Colorectal Cancer Models: From Carcinogens to Xenografts

Posted by: Elie J. Diner, Ph.D. -

Colorectal cancer (CRC) is common and deadly, making up an estimated 7.9% of all new cancer cases and 8.7% of all cancer deaths in the U.S. last year.1 Cancer mortality often results from metastasis, which for colorectal cancer, happens frequently; ...

Read More

Certis Oncology Solutions Recently Featured in Cancer Cell Journal for Innovation in Personalized Cancer Medicine

Posted by: Mary Catania -

Functional Precision Oncology: Testing Tumors with Drugs to Identify Vulnerabilities and Novel Combinations  

Read More

How to Identify High-Quality Hits Early On: Your Guide to Ensuring Reproducible In Vitro Oncology Studies

Posted by: Elie J. Diner, Ph.D. -

In the past several decades, oncology drug development has had some major successes, from the approval of game-changing therapeutics such as rituximab and trastuzumab in the late-90s to the first tumor-agnostic approval for pembrolizumab in 2017.1...

Read More

Mimicking the "Seed and Soil:" The State of PDX Models of Breast Cancer Metastases

Posted by: Elie J. Diner, Ph.D. -

Why do the quaintest analogies stick to biology’s most morbid phenomena? Look no further than English surgeon Stephen Paget’s “seed and soil” model for breast cancer metastasis for a prototypical example. In his 1889 publication in the Lancet, Paget...

Read More

Sarcomas vs. pharmaceutical science

Posted by: Mary Catania -

THE RIGHT TUMOR MODELS BRING GREATER CERTAINTY TO DRUG CANDIDATE SELECTION  

Read More

Making precision oncology more personal

Posted by: Elie J. Diner, Ph.D. -

FROM GENETIC TESTING FOR CANCER TO FUNCTIONAL, PATIENT-DERIVED MODELS Genetic testing for cancer has rapidly become an important and routine part of oncology treatment. It’s driven the rise of precision oncology, where clinicians seek to match the...

Read More

Predicting Therapeutic Response & Drug Resistance with O-PDX

Posted by: Elie J. Diner, Ph.D. -

AACR 2021 Poster #2929: Predicting Patient’s Therapeutic Response and Acquired Drug Resistance with Orthotopic Patient-Derived Xenografts (O-PDX) Patient-derived xenografts (PDX) are a commonly used in vivo model that can provide clinically...

Read More

The Subcutaneous Xenograft vs Orthotopic Xenograft Debate

Posted by: Elie J. Diner, Ph.D. -

Subcutaneous vs Orthotopic Xenografts: Identifying Clinically Relevant Models for Making More Accurate, Personalized Cancer Treatment Decisions In our last blog, we explored some of the current gaps in personalized medicine and how patient-derived...

Read More

Making More Accurate, Personalized Cancer Treatment Decisions With Clinically Relevant PDX Models, Part 1

Posted by: Elie J. Diner, Ph.D. -

In the past few decades, researchers and clinicians have gained a deep understanding of the biology behind tumor growth and metastasis and the clinical course for many different types of cancers. Despite these advancements, cancers are still treated...

Read More

Precision Oncology as a Model for Bridging the “Valley of Death”

Posted by: Kristein King -

A persistent challenge in anti-cancer drug development remains translation from animal studies to human clinical trials. A shocking 57% of late-stage oncology trials fail due to inadequate efficacy. These failures amount to billions of dollars in...

Read More